Literature DB >> 25946296

Lenvatinib in radioiodine-refractory thyroid cancer.

Hyo Jin Lee, Hwan-Jung Yun, Samyong Kim.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25946296     DOI： 10.1056/NEJMc1503150

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.

Authors:  Keisuke Enomoto; Xuguang Zhu; Sunmi Park; Li Zhao; Yuelin J Zhu; Mark C Willingham; Jun Qi; John A Copland; Paul Meltzer; Sheue-Yann Cheng
Journal:  J Clin Endocrinol Metab       Date:  2017-07-01       Impact factor: 5.958

2.  Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model.

Authors:  Xuguang Zhu; Keisuke Enomoto; Li Zhao; Yuelin J Zhu; Mark C Willingham; Paul Meltzer; Jun Qi; Sheue-Yann Cheng
Journal:  Clin Cancer Res       Date:  2016-07-20       Impact factor: 12.531

3.  Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.

Authors:  Bo Shi; Wenbiao Ma; Hongshuai Pan; Yang Shi; Huan Zhang; Shenghai Xing
Journal:  Front Pharmacol       Date:  2022-06-30       Impact factor: 5.988
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.